Skip to content

The effects of rTMS on cortical excitability and brain function in patients with cognitive dysfunction after stroke were analyzed based on EEG

The effects of rTMS on cortical excitability and brain function in patients with cognitive dysfunction after stroke were analyzed based on EEG

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049851
Enrollment
Unknown
Registered
2021-08-10
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive dysfunction after stroke

Interventions

High frequency rTMS group:No
The low frequency rTMS group:No
Cognitive function training group:No

Sponsors

Shanghai Tongren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The first onset, the course of disease >= 3 months; 2. The vital signs are stable, and the symptoms do not progress; 3. Consciousness, no serious aphasia and obvious cognitive dysfunction before the onset (11 points < MoCA score < 26 points, can cooperate with the completion of treatment and evaluation; 4. No stroke lesions in key parts (hippocampus, thalamus, large cortical lesions) 5. Age < 70 years old, all subjects are right-handed; 6. All patients participated voluntarily and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Multiple episodes; 2. There is a history of transcranial surgery; 3. Patients with metal foreign bodies or implanted electronic devices in the body, which are contraindications to rTMS treatment; 4. History of traumatic brain injury, cerebral hemorrhage, epilepsy, cognitive impairment and mental illness in the past; 5. Severe white matter degeneration Fazekas scale score> 1; 6. Cognitive deficits caused by other reasons (such as drug abuse, heavy drinking, etc.); 7. Combined with severe liver, kidney, heart disease or other serious physical diseases; 8. Patients with severe hearing, vision, language impairment and other reasons who cannot cooperate with clinical examination.

Design outcomes

Primary

MeasureTime frame
Montreal Cognitive Assessment;Stroop color word interference test;

Secondary

MeasureTime frame
Wired Quiz;Event-related potential P300;Resting state electroencephalography;Resting state functional magnetic resonance;

Countries

China

Contacts

Public ContactZhang Jingjing

Shanghai Tongren Hospital

hdyyzjj@163.com+86 18721990028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026